Treatment: antiarrhythmics (flecainide, propafenone, sotalol, digoxin, dronedarone)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Flecainide, propafenone (class I)
Before starting
- Serum electrolytes (potassium)
- Serum magnesium
- Serum creatinine (calculate Cockcroft–Gault clearance)
- ASTif neededPatient started on propafenone: contraindicated in cirrhosis, reduced starting dose in moderate hepatic impairment, stop if liver enzymes exceed 3 times normal (SmPC) [3].
- ALT (propafenone)if neededPatient started on propafenone: contraindicated in cirrhosis, reduced starting dose in moderate hepatic impairment, stop if liver enzymes exceed 3 times normal (SmPC) [3].
At least once a year (atrial fibrillation)
- Serum electrolytes (potassium)
- Serum creatinine (calculate Cockcroft–Gault clearance)
- Flecainide (blood level) (renal impairment or older patient)if neededIn renal failure and in older people, slowed elimination exposes to accumulation: the SmPC (RCP) recommends “treatment monitoring” [4]. Can be measured under the code for antiarrhythmics not specifically listed [5].
Sotalol
Before starting, and before each dose change
- Serum electrolytes (potassium)
- Serum magnesium
- Serum creatinine (calculate Cockcroft–Gault clearance)
At least once a year, and without waiting if a potassium-lowering drug is added (diuretic, stimulant laxative, corticosteroid)
- Serum electrolytes (potassium)
- Serum creatinine (calculate Cockcroft–Gault clearance)
Digoxin
Before starting
- Serum electrolytes (potassium)
- Serum creatinine (calculate Cockcroft–Gault clearance)
- TSH (if known or suspected thyroid dysfunction)if needednon-French guidelineThe NHS pharmacy service (SPS) measures thyroid function before digoxin, as the dose is adjusted in case of thyroid dysfunction [12]; the Dutch formulary also asks for this adjustment [10]. The French SmPC (RCP) lists hypothyroidism among the situations of increased sensitivity [13]; HAS provides for TSH at diagnosis of atrial fibrillation, not in the tests specific to digoxin [7].
- Serum magnesium (if long-term PPI or diuretic)if needednon-French guidelineThe NHS pharmacy service (SPS) measures magnesium before digoxin and then every year, more often with long-term PPI or another drug exposing to hypomagnesaemia, as it favours toxicity [12]; diuretics are among these [11], and the Dutch formulary flags the same risk [10]. The French digoxin SmPC (RCP) does not mention magnesium [13] and HAS retains serum potassium and creatinine [7].
- Serum calcium (if calcium or vitamin D co-prescribed, or known hypercalcaemia)if neededHypercalcaemia increases sensitivity to digoxin [12,13]. The French SmPC (RCP) asks, where appropriate, for a calcium check with oral calcium supplements, in particular combined with vitamin D [13]; the NHS pharmacy service (SPS) measures calcium before treatment and then every year in everyone [12]; HAS does not list it [7].
End of the first week, at least 8 hours after the last dose (older patient or renal impairment)
- Serum digoxinif neededNecessary in older people and in renal failure to adjust the dose, at steady state (end of the first week) [7,13].
- Serum electrolytes (potassium)
Then periodically (at least once a year; more often in older patients, renal impairment or on a diuretic)
- Serum electrolytes (potassium)
- Serum creatinine (calculate Cockcroft–Gault clearance)
- Serum digoxin (signs of overdose, interaction, renal deterioration)if neededAnorexia, nausea, vomiting, diarrhoea or ECG abnormality [13]; visual or psychiatric disturbances in older people [13]; addition of a drug that raises serum digoxin (amiodarone, verapamil, quinidine or hydroquinidine, clarithromycin, erythromycin, telithromycin, itraconazole, ritonavir [13], propafenone [3], dronedarone [14]) or lowers it (St John's wort, sulfasalazine, carbamazepine) [13]; functional renal failure in heart failure [13]; pregnancy near term [13].
- Serum magnesium (if long-term PPI or diuretic)if needednon-French guidelineThe NHS pharmacy service (SPS) measures magnesium every year on digoxin, more often with long-term PPI or another drug exposing to hypomagnesaemia, as it favours toxicity [12]; diuretics are among these [11], and the Dutch formulary flags the same risk [10]. The French digoxin SmPC (RCP) does not mention magnesium [13] and HAS retains serum potassium and creatinine [7].
- Serum calcium (if calcium or vitamin D co-prescribed, or known hypercalcaemia)if neededHypercalcaemia increases sensitivity to digoxin [12,13]. The French SmPC (RCP) asks, where appropriate, for a calcium check with oral calcium supplements, in particular combined with vitamin D [13]; the NHS pharmacy service (SPS) measures calcium every year in everyone [12]; HAS does not list it [7].
Do not order
Dronedarone (Multaq)
Before starting
- AST
- ALT
- Serum creatinine (calculate Cockcroft–Gault clearance)
- Serum electrolytes (potassium)
- Serum magnesium
- Serum β-hCG (woman of childbearing potential)if neededWoman of childbearing potential: the SmPC (RCP) asks to make sure she is not pregnant before starting dronedarone, and then effective contraception [14].
On D7
- ALT
- Serum creatinine
At 1 month, then every month up to 6 months, then at 9 and 12 months, then regularly
- ALT
- Serum creatinine (renal function regularly)
- Serum electrolytes (potassium)if neededPotassium-lowering diuretic, vomiting, diarrhoea: any potassium or magnesium deficit must be corrected during treatment (SmPC) [14].
- Serum magnesium (during treatment, if risk of deficiency)if neededPotassium-lowering diuretic, vomiting, diarrhoea: any potassium or magnesium deficit must be corrected during treatment (SmPC) [14].
Amiodarone
- See the "Treatment: amiodarone" page (TSH, liver function tests, electrolytes).
Sources (18)
- Assurance maladie. Open Medic 2024, base « nombre de consommants » par code ATC5 (fichier NB_2024_atc5), open-data-assurance-maladie.ameli.fr, téléchargé le 23/10/2026, relu le 24/10/2026.
- Assurance maladie. Cartographie des pathologies et des dépenses, effectifs 2024 (data.ameli.fr, jeu « effectifs »), consulté le 24/10/2026.
- ANSM. Résumé des caractéristiques du produit RYTHMOL 300 mg, comprimé pelliculé sécable (propafénone) (rubriques 4.2 à 4.5), texte mis à jour le 02/06/2023. Base de données publique des médicaments (CIS 66843923), consultée le 11/10/2026.
- ANSM. Résumé des caractéristiques du produit FLECAINE L.P. 200 mg, gélule à libération prolongée (flécaïnide) (rubriques 4.2, 4.3, 4.4 et 4.5), texte mis à jour le 27/07/2026. Base de données publique des médicaments (CIS 65017848), consultée le 11/10/2026.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0327 (digoxine) et 1678 (antiarythmiques non nommément inscrits).
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414.
- Haute Autorité de santé. Guide du parcours de soins : fibrillation atriale. Février 2014.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156.
- National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. NICE guideline NG196, publiée le 27 avril 2021, mise à jour le 30 juin 2021.
- Zorginstituut Nederland. Farmacotherapeutisch Kompas (Pays-Bas) : flécaïnide, propafénone, sotalol, digoxine.
- ANSM. Résumé des caractéristiques du produit SOTALEX 80 mg, comprimé sécable (sotalol) (rubriques 4.2, 4.3, 4.4 et 4.5), texte mis à jour le 04/11/2022. Base de données publique des médicaments (CIS 62519799), consultée le 11/10/2026.
- NHS Specialist Pharmacy Service. Digoxin monitoring. Republié le 27 décembre 2023.
- ANSM. Résumé des caractéristiques du produit DIGOXINE NATIVELLE 0,25 mg, comprimé (digoxine) (rubriques 4.2, 4.3, 4.4 et 4.5), texte mis à jour le 01/09/2025. Base de données publique des médicaments (CIS 67681303), consultée le 11/10/2026.
- Agence européenne des médicaments. Résumé des caractéristiques du produit MULTAQ 400 mg, comprimés pelliculés (dronédarone), annexe I de l'EPAR (version française).
- National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. NICE guideline NG106, publiée le 12 septembre 2018, mise à jour le 3 septembre 2025.
- Bundesärztekammer, Kassenärztliche Bundesvereinigung, AWMF. Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz, version 4.0, 2023 (Allemagne).
- Base de données publique des médicaments. MULTAQ 400 mg, comprimé pelliculé (CIS 69213011) : statut de commercialisation, remboursement et avis de la Commission de la transparence.
- NHS Specialist Pharmacy Service. Dronedarone monitoring. Republié le 5 décembre 2025.